Pramlintide: Uses, Mechanism, and Side Effects

For people with diabetes who still struggle with blood sugar control despite carefully managed mealtime insulin, options beyond insulin itself are limited. Pramlintide is one of the few approved add-on therapies designed specifically for this situation.

Key takeaways

• Pramlintide is an amylin analog approved as an add-on to mealtime insulin therapy.
• It is marketed under the brand name SymlinPen.
• The label carries a boxed warning.
• Sixty-six registered trials have studied pramlintide, including work on artificial pancreas systems and weight effects.
• Reported reactions in safety databases include blood glucose changes, kidney-related events, and gastrointestinal symptoms.

What Pramlintide Is

Pramlintide is a synthetic analog of human amylin, a hormone normally released by the pancreas alongside insulin after eating. In healthy people, amylin and insulin are secreted together in response to food intake. People with type 1 or type 2 diabetes have reduced secretion of both hormones from pancreatic beta cells, which pramlintide is designed to help replace.

What Pramlintide Is Approved For

Pramlintide, sold as SymlinPen, is approved as an adjunctive treatment for adults with type 1 or type 2 diabetes who use mealtime insulin. It is specifically intended for those who have not achieved adequate glucose control despite optimal insulin therapy on its own. The label carries a boxed warning, which prescribers and patients should be aware of.

What the Evidence Shows

Pramlintide has been studied across 66 registered clinical trials. One completed trial examined how hyperglycemia affects gastric emptying in interaction with pramlintide. A separate phase 2 trial, also completed, looked at the drug's long-term effect on body weight and its safety and tolerability in obese subjects. More recent research has explored pramlintide's role alongside insulin in automated dual-hormone artificial pancreas systems for type 1 diabetes.

Reported Side Effects

Safety reports associated with pramlintide are dominated by changes in blood glucose, with increased blood glucose the most frequently reported reaction. Kidney-related events, including acute kidney injury, chronic kidney disease, and renal failure, also appear frequently in these reports. Other commonly reported reactions include nausea, dyspnoea, fatigue, and hypertension. These figures reflect the number of reports submitted to a safety surveillance system, not confirmed rates of incidence or proof that pramlintide caused the reaction.